In studies of injectable and oral Wegovy in people with obesity or overweight (but not necessarily PCOS), participants lost almost 6% of their body weight at three months, and nearly 11% at six months
Tirzepatide is the first dual GLP-1 and GIP receptor agonist offering targeted therapy for diabetes and obesity
Given substantial heterogeneity in study designs, populations, and outcomes, formal GRADE assessment with numerical ratings was not feasible
Similar in vitro work showed that HGF promoted dendritic arborization in hippocampal neurons, an effect that could be blocked by NMDA receptor antagonists and was dependent on intracellular calcium and CaMKII activity [2]
Available from: Weber AG, Chau AS, Egeblad M, Barnes BJ, Janowitz T